Selective toxicity of tumor treating fields to melanoma: an in vitro and in vivo study

被引:0
|
作者
Yunhui Jo
Sang-Gu Hwang
Yeung Bae Jin
Jiwon Sung
Youn Kyoung Jeong
Jeong Hwa Baek
Jae-Min Cho
Eun Ho Kim
Myonggeun Yoon
机构
[1] Korea Institute of Radiological and Medical Sciences,Division of Radiation Biomedical Research
[2] Korea University,Department of Bio
[3] Korea Research Institute of Bioscience and Biotechnology,Convergence Engineering
[4] Korea Institute of Radiological and Medical Sciences,National Primate Research Center
来源
Cell Death Discovery | / 4卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Tumor treating fields (TTFs) are a newly developed cancer therapy technology using an alternating electric field that may be a possible candidate for overcoming the limitations of conventional treatment methods currently used in cancer treatment. Although clinical results using TTFs appear promising, concerns regarding side effects must be clarified to demonstrate the effectiveness of this treatment method. To investigate the side effects of TTF treatment, the damage to normal cell lines and normal tissue of a mouse model was compared with the damage to tumor cells and tumors in a mouse model after TTF treatment. No serious damage was found in the normal cells and normal tissues of the mouse model, suggesting that the side effects of TTF treatment may not be serious. Our evidence based on in vitro and in vivo experiments suggests that TTF may cause selective damage to cancer cells, further demonstrating the potential of TTF as an attractive alternative to conventional cancer treatment modalities.
引用
收藏
相关论文
共 50 条
  • [1] Selective toxicity of tumor treating fields to melanoma: an in vitro and in vivo study
    Jo, Yunhui
    Hwang, Sang-Gu
    Jin, Yeung Bae
    Sung, Jiwon
    Jeong, Youn Kyoung
    Baek, Jeong Hwa
    Cho, Jae-Min
    Kim, Eun Ho
    Yoon, Myonggeun
    CELL DEATH DISCOVERY, 2018, 4
  • [3] In vitro and in vivo investigation of tumor treating fields for treatment of spinal metastasis
    Tatsui, Claudio Esteves
    Ledbetter, Daniel
    Alvarez-Breckenridge, Christopher
    CANCER RESEARCH, 2023, 83 (07)
  • [4] In vitro and in vivo evidence for the safety and efficacy of Tumor Treating Fields (TTFields) in combination with sorafenib
    Davidi, Shiri
    Tempel-Brami, Catherine
    Munster, Mijal
    Shteingauz, Anna
    Zeevi, Einav
    Schneiderman, Rosa
    Voloshin, Tali
    Giladi, Moshe
    Kinzel, Adrian
    Weinberg, Uri
    Palti, Yoram
    CANCER RESEARCH, 2020, 80 (16)
  • [5] Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo
    Davidi, Shiri
    Jacobovitch, Sara
    Shteingauz, Anna
    Martinez-Conde, Antonia
    Braten, Ori
    Tempel-Brami, Catherine
    Zeevi, Einav
    Frechtel-Gerzi, Roni
    Ene, Hila
    Dor-On, Eyal
    Voloshin, Tali
    Tzchori, Itai
    Haber, Adi
    Giladi, Moshe
    Kinzel, Adrian
    Weinberg, Uri
    Palti, Yoram
    CANCERS, 2022, 14 (12)
  • [6] Tumor treating fields (TTFields) in combination with sorafenib inhibit hepatocellular carcinoma in vitro and in vivo
    Potter, Wyatt
    Davidi, Shiri
    Jacobovitch, Sara
    Shteingauz, Anna
    Tempel-Brami, Catherine
    Zeevi, Einav
    Dor-On, Eyal
    Schneiderman, Rosa S.
    Voloshin, Tali
    Tzchori, Itai
    Haber, Adi
    Giladi, Moshe
    Kinzel, Adrian
    Weinberg, Uri
    Palti, Yoram
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [7] Tumor treating fields effects on the blood-brain barrier in vitro and in vivo.
    Salvador, Ellaine
    Kessler, Almuth
    Hoermann, Julia
    Domroese, Dominik
    Schaeffer, Clara
    Burek, Malgorzata
    Tempel-Brami, Catherine
    Voloshin, Tali
    Giladi, Moshe
    Ernestus, Ralf-Ingo
    Loehr, Mario
    Foerster, Carola
    Hagemann, Carsten
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Effectiveness of Tumor Treating Fields plus Cisplatin/Pemetrexed Combination in Mesothelioma, in Vitro and in Vivo
    Mumblat, H.
    Martinez, A.
    Munster, M.
    Dor-On, E.
    Schneiderman, R.
    Porat, Y.
    Voloshin, T.
    Davidi, S.
    Blatt, R.
    Shteingauz, A.
    Tempel-Brami, C.
    Zeevi, E.
    Lajterer, C.
    Shmueli, Y.
    Danilov, S.
    Haber, A.
    Giladi, M.
    Weinberg, U.
    Palti, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S386 - S386
  • [9] In vitro and in vivo efficacy and safety of tumor treating fields (TTFields) and sorafenib combination in hepatocellular carcinoma
    Davidi, Shiri
    Tempel-Brami, Catherine
    Munster, Mijal
    Gotlib, Karnit
    Zeevi, Einav
    Schneiderman, Rosa S.
    Voloshin, Tali
    Giladi, Moshe
    Kinzel, Adrian
    Kirson, Eilon D.
    Weinberg, Uri
    Palti, Yoram
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [10] Tumor treating fields (TTFields) affect blood brain barrier (BBB) integrity in vitro and in vivo
    Kessler, Almuth F.
    Schaeffer, Clara M.
    Burek, Malgorzata
    Ruschig, Ursula
    Tempel-Brami, Catherine
    Voloshin, Tali
    Giladi, Moshe
    Salvador, Ellaine
    Ernestus, Ralf-Ingo
    Loehr, Mario
    Foerster, Carole
    Hagemann, Carsten
    CANCER RESEARCH, 2019, 79 (13)